Table 5

 Dose-response relation between categories of cumulative daily dispensed doses of statins and fibrates during the year preceding the index date and the risk of peripheral neuropathy. Province of Varese, Italy, 1997–1999.

CasesControlsOR†(95% CI)†
Number (%)Number (%)
†Odds ratios and 95% confidence intervals. Estimates are adjusted for the presence of thyroid disease, diabetes, anaemia, chronic renal failure and connective tissue disease. *p<0.05.
Statins
No use1945 (95.34)34707 (96.30)1.00(reference)
1–90 days18 (0.88)299 (0.83)1.00(0.62 to 1.62)
91–180 days22 (1.08)335 (0.93)1.10(0.71 to 1.71)
181–270 days40 (1.96)559 (1.55)1.21(0.87 to 1.68)
⩾271 days15 (0.74)141 (0.39)1.88*(1.10 to 3.23)
Trend test: p = 0.0311
Fibrates
No use2007 (98.38)35701 (99.06)1.00(reference)
1–90 days8 (0.39)89 (0.25)1.43(0.69 to 2.97)
91–180 days19 (0.93)194 (0.54)1.58(0.98 to 2.56)
⩾1816 (0.29)57 (0.16)1.60(0.68 to 3.75)
Trend test: p = 0.0236